Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,570 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Crystal structure of heliorhodopsin.
Shihoya W, Inoue K, Singh M, Konno M, Hososhima S, Yamashita K, Ikeda K, Higuchi A, Izume T, Okazaki S, Hashimoto M, Mizutori R, Tomida S, Yamauchi Y, Abe-Yoshizumi R, Katayama K, Tsunoda SP, Shibata M, Furutani Y, Pushkarev A, Béjà O, Uchihashi T, Kandori H, Nureki O. Shihoya W, et al. Among authors: hashimoto m. Nature. 2019 Oct;574(7776):132-136. doi: 10.1038/s41586-019-1604-6. Epub 2019 Sep 25. Nature. 2019. PMID: 31554965
Zinc Binding to Heliorhodopsin.
Hashimoto M, Katayama K, Furutani Y, Kandori H. Hashimoto M, et al. J Phys Chem Lett. 2020 Oct 15;11(20):8604-8609. doi: 10.1021/acs.jpclett.0c02383. Epub 2020 Sep 28. J Phys Chem Lett. 2020. PMID: 32940480
Specific zinc binding to heliorhodopsin.
Hashimoto M, Miyagawa K, Singh M, Katayama K, Shoji M, Furutani Y, Shigeta Y, Kandori H. Hashimoto M, et al. Phys Chem Chem Phys. 2023 Jan 27;25(4):3535-3543. doi: 10.1039/d2cp04718g. Phys Chem Chem Phys. 2023. PMID: 36637167
Internal Proton Transfer in the Activation of Heliorhodopsin.
Singh M, Hashimoto M, Katayama K, Furutani Y, Kandori H. Singh M, et al. Among authors: hashimoto m. J Mol Biol. 2024 Mar 1;436(5):168273. doi: 10.1016/j.jmb.2023.168273. Epub 2023 Sep 12. J Mol Biol. 2024. PMID: 37709010
C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma.
Uchimoto T, Matsuda T, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Saruta M, Hashimoto M, Higashio T, Tsuchida S, Nishimura K, Tsujino T, Nakamura K, Fukushima T, Nishio K, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Fujita K, Kimura T, Ohno Y, Shiroki R, Uemura H, Azuma H. Uchimoto T, et al. Among authors: hashimoto m. Target Oncol. 2024 May 28. doi: 10.1007/s11523-024-01068-7. Online ahead of print. Target Oncol. 2024. PMID: 38807017
Effectiveness and safety of enzalutamide and apalutamide in the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC): a multicenter retrospective study.
Hara S, Mori K, Fukuokaya W, Tomomasa N, Oguchi T, Takahashi Y, Saito S, Katami J, Sano T, Kadena S, Hashimoto M, Yata Y, Nishi E, Suhara Y, Takamizawa S, Kurawaki S, Suzuki H, Miyajima K, Iwatani K, Urabe F, Ito K, Yanagisawa T, Tsuzuki S, Shimomura T, Kimura T. Hara S, et al. Among authors: hashimoto m. Int J Clin Oncol. 2024 May 20. doi: 10.1007/s10147-024-02548-6. Online ahead of print. Int J Clin Oncol. 2024. PMID: 38769191
4,570 results